Ethicon Surgical Innovations Lab Kicks Off: Benefits Surgeons Unable to Travel

Ethicon*, part of the Johnson & Johnson Medical Devices Companies**, today announced its state-of-the-art and fully functional surgical lab on wheels will travel to hospitals in 70 locations across America providing surgeons and other healthcare professionals the opportunity for hands-on learning experiences and demonstrations with the newest technologies for colorectal, bariatric, gynecological and thoracic procedures.

ethicon

The Ethicon Surgical Innovations Lab will showcase the company’s portfolio of advanced energy solutions including the recently launched ENSEAL X1 Curved Jaw Tissue Sealer, which continuously senses changes in tissue and responds with the optimized amount of energy during surgery.[i]

The groundbreaking ECHELON CIRCULAR Powered Stapler will also be among the surgical stapler technology featured on the more than 850-square-foot mobile lab. In recent studies, the ECHELON CIRCULAR, which is the world’s first circular powered stapler, has been shown to reduce anastomotic leaks, a relatively common and potentially life-threatening complication of colorectal surgery, by nearly 74% compared to manual circular staplers.[ii] Surgical staplers utilize specialized staples to close off and cut through organs, tissue and blood vessels in both laparoscopic and traditional surgery.

“After a year like no other, we’re eager to bring these latest advances directly to surgeons in their own communities and continue building on our trusted legacy of innovation to shape the future of surgery,” said Nefertiti Greene, President, US Ethicon. “Ethicon has a significant research, development and educational focus on improving patient outcomes, reducing life-threatening and costly complications, and streamlining surgery through innovations in surgical stapling technology and energy-based devices.”

Over the last year, the COVID-19 pandemic has limited opportunities for surgeons and other practitioners to travel for in-person learning experiences. The Ethicon Surgical Innovations Lab mobile tour is being conducted to help surgeons and hospitals stay current on the latest technologies and the science behind them from the convenience of their own cities. Surgeons will be able to use the various devices on inanimate tissue and engage with key faculty, engineers and researchers on the technical aspects of the products, as well as the body of evidence that supports them.

The Ethicon Surgical Innovation Lab was recently in Dayton, Ohio at Kettering Health for one of its first stops on the national tour.

“The mobile lab was an amazing experience. The benefit for our surgeons and staff to be able to get hands-on training and education cannot be measured. I encourage anyone who has the opportunity to visit the lab to definitely do so. We walked away with very valuable knowledge and understanding of the new technology being offered. Definitely a must see for clinicians and staff,” said Jerry Willis, Strategic Sourcing Manager Surgical Services, Kettering Health.

[i]Claim #134168-210203

[ii]Sylla, P., Sagar, P., Johnston, S.S. et al. Outcomes associated with the use of a new powered circular stapler for left-sided colorectal reconstructions: a propensity score matching-adjusted indirect comparison with manual circular staplers. Surg Endosc(2021). https://doi.org/10.1007/s00464-021-08542-7


[1]Claim #134168-210203

[1]Sylla, P., Sagar, P., Johnston, S.S. et al. Outcomes associated with the use of a new powered circular stapler for left-sided colorectal reconstructions: a propensity score matching-adjusted indirect comparison with manual circular staplers. Surg Endosc(2021). https://doi.org/10.1007/s00464-021-08542-7

*Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates. All other trademarks are the property of their respective owners.

**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopedics, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.

SourceEthicon

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version